Fate Therapeutics
FATE
#9566
Rank
โ‚ฌ0.10 B
Marketcap
0,84ย โ‚ฌ
Share price
-9.01%
Change (1 day)
-7.97%
Change (1 year)

EPS for Fate Therapeutics (FATE)

EPS in 2026 (TTM): -0,90ย โ‚ฌ

According to Fate Therapeutics 's latest financial reports the company's current EPS (TTM) is -0,96ย โ‚ฌ. In 2025 the company made an earnings per share (EPS) of -1,05ย โ‚ฌ an increase over its 2024 EPS that were of -1,50ย โ‚ฌ.

EPS history for Fate Therapeutics from 2014 to 2026

Annual EPS

Year EPS Change
2026 (TTM)-0,90ย โ‚ฌ-13.81%
2025-1,05ย โ‚ฌ-29.88%
2024-1,50ย โ‚ฌ
2022-2,65ย โ‚ฌ30.49%
2021-2,03ย โ‚ฌ7.21%
2020-1,90ย โ‚ฌ45.45%
2019-1,30ย โ‚ฌ19.17%
2018-1,09ย โ‚ฌ17.65%
2017-0,93ย โ‚ฌ-3.77%
2016-0,97ย โ‚ฌ-12.4%
2015-1,10ย โ‚ฌ-3.97%
2014-1,15ย โ‚ฌ

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Becton Dickinson
BDX
3,28ย โ‚ฌ-442.86%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-2,40ย โ‚ฌ 150.48%๐Ÿ‡บ๐Ÿ‡ธ USA
PTC Therapeutics
PTCT
-1,19ย โ‚ฌ 24.76%๐Ÿ‡บ๐Ÿ‡ธ USA
Neurocrine Biosciences
NBIX
6,35ย โ‚ฌ-763.81%๐Ÿ‡บ๐Ÿ‡ธ USA
Avidity Biosciences
RNAM
-3,81ย โ‚ฌ 298.10%๐Ÿ‡บ๐Ÿ‡ธ USA